Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Day One Biopharmaceuticals (DAWN) Shares Outstanding (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Shares Outstanding for 4 consecutive years, with $103.0 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.85% year-over-year to $103.0 million; the TTM value through Dec 2025 reached $103.0 million, up 1.85%, while the annual FY2025 figure was $103.0 million, 1.85% up from the prior year.
  • Shares Outstanding was $103.0 million for Q4 2025 at Day One Biopharmaceuticals, roughly flat from $102.7 million in the prior quarter.
  • The five-year high for Shares Outstanding was $103.0 million in Q4 2025, with the low at $11.5 million in Q2 2022.
  • Historically, Shares Outstanding has averaged $79.2 million across 4 years, with a median of $87.3 million in 2023.
  • The largest annual shift saw Shares Outstanding skyrocketed 560.87% in 2024 before it grew 1.85% in 2025.
  • Over 4 years, Shares Outstanding stood at $73.5 million in 2022, then increased by 18.74% to $87.2 million in 2023, then increased by 15.92% to $101.1 million in 2024, then rose by 1.85% to $103.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $103.0 million in Q4 2025, $102.7 million in Q3 2025, and $102.4 million in Q2 2025.